These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37787490)

  • 1. RAF1 mutation leading to hypertrophic cardiomyopathy in a Chinese family with a history of sudden cardiac death: A diagnostic insight into Noonan syndrome.
    Zheng J; Peng L; Cheng R; Li Z; Xie J; Huang E; Cheng J; Zhao Q
    Mol Genet Genomic Med; 2024 Jan; 12(1):e2290. PubMed ID: 37787490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular autopsy and clinical family screening in a case of sudden cardiac death reveals ACTN2 mutation related to hypertrophic/dilated cardiomyopathy and a novel LZTR1 variant associated with Noonan syndrome.
    Kraoua L; Jaouadi H; Allouche M; Achour A; Kaouther H; Ahmed HB; Chaker L; Maazoul F; Ouarda F; Zaffran S; M'rad R
    Mol Genet Genomic Med; 2022 Jul; 10(7):e1954. PubMed ID: 35656879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
    Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
    Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
    Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
    Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted/exome sequencing identified mutations in ten Chinese patients diagnosed with Noonan syndrome and related disorders.
    Xu S; Fan Y; Sun Y; Wang L; Gu X; Yu Y
    BMC Med Genomics; 2017 Oct; 10(1):62. PubMed ID: 29084544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
    Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
    Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
    Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
    J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK Inhibition in a Newborn with
    Mussa A; Carli D; Giorgio E; Villar AM; Cardaropoli S; Carbonara C; Campagnoli MF; Galletto P; Palumbo M; Olivieri S; Isella C; Andelfinger G; Tartaglia M; Botta G; Brusco A; Medico E; Ferrero GB
    Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel likely pathogenic TPM1 variant linked to hypertrophic cardiomyopathy in a family with sudden cardiac death.
    Azimi A; Soveizi M; Salmanipour A; Mozafarybazargany M; Ghaffari Jolfayi A; Maleki M; Kalayinia S
    ESC Heart Fail; 2024 Oct; 11(5):3180-3190. PubMed ID: 38874371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
    Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
    J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical, severe hypertrophic cardiomyopathy in a newborn presenting Noonan syndrome harboring a recurrent heterozygous MRAS variant.
    Pires LVL; Bordim RA; Maciel MBR; Tanaka ACS; Yamamoto GL; Honjo RS; Kim CA; Bertola DR
    Am J Med Genet A; 2021 Oct; 185(10):3099-3103. PubMed ID: 34080768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
    Mori AA; Castro LR; Bortolin RH; Bastos GM; Oliveira VF; Ferreira GM; Hirata TDC; Fajardo CM; Sampaio MF; Moreira DAR; Pachón-Mateos JC; Correia EB; Sousa AGMR; Brión M; Carracedo A; Hirata RDC; Hirata MH
    Forensic Sci Int Genet; 2021 May; 52():102478. PubMed ID: 33588347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertrophic cardiomyopathy in Noonan syndrome.
    Nishikawa T; Ishiyama S; Shimojo T; Takeda K; Kasajima T; Momma K
    Acta Paediatr Jpn; 1996 Feb; 38(1):91-8. PubMed ID: 8992870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
    Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
    Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
    Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
    Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation.
    Hopper RK; Feinstein JA; Manning MA; Benitz W; Hudgins L
    Am J Med Genet A; 2015 Apr; 167A(4):882-5. PubMed ID: 25706034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy.
    Caiazza M; Rubino M; Monda E; Passariello A; Fusco A; Cirillo A; Esposito A; Pierno A; De Fazio F; Pacileo R; Evangelista E; Pacileo G; Russo MG; Limongelli G
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32824488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene mutation and clinical phenotype analysis of patients with Noonan syndrome and hypertrophic cardiomyopathy].
    Liu XH; Ding WW; Han L; Liu XR; Xiao YY; Yang J; Mo Y
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):780-784. PubMed ID: 29050118
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
    Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
    J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.